Targeted Degradation of PARP14 Using a Heterobifunctional Small Molecule

Area of Science:

• Immunology
• Molecular Biology
• Biochemistry

Background:

• Poly(ADP-ribose) polymerase 14 (PARP14) is an interferon-stimulated gene overexpressed in various cancers.
• PARP14 influences macrophage polarization towards a pro-tumor phenotype and suppresses anti-tumor immunity by modulating IFN-γ and IL-4 signaling.
• While catalytic inhibitors of PARP14 exist, the roles of its non-enzymatic domains in immune regulation remain unclear.

Purpose of the Study:

• To investigate the immunological functions of PARP14 beyond its catalytic activity.
• To develop novel therapeutic strategies targeting PARP14 for cancer treatment.

Main Methods:

• Discovery of a heterobifunctional small molecule targeting PARP14.
• The molecule is designed based on a catalytic inhibitor that binds to the NAD+-binding site of PARP14.
• The molecule recruits cereblon (CRBN) to induce ubiquitination and subsequent degradation of PARP14.

Main Results:

• A novel heterobifunctional molecule was synthesized, capable of targeting PARP14 for degradation.
• This molecule leverages the ubiquitin-proteasome system via cereblon recruitment.
• The approach offers selective degradation of PARP14, distinct from traditional catalytic inhibition.

Conclusions:

• The developed molecule provides a novel approach to target PARP14 by inducing its degradation.
• This strategy may overcome limitations of catalytic inhibitors and offers a new avenue for cancer immunotherapy.
• Further research into the non-enzymatic roles of PARP14 and the efficacy of this degradation approach is warranted.